Anika Moorjani
Researcher
Formerly Arkansas Affiliated with UAMS through 2021; recent publications list University of Oregon, Impact Technology Development (United States).
Unknown Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Anika Moorjani's research focuses on the investigation of novel therapeutic agents for breast cancer, particularly targeting stem-like cells. Her work involves the synthesis and evaluation of modified salinomycin analogs, exploring their efficacy in both two-dimensional and three-dimensional breast cancer models. This research aims to identify compounds with enhanced antitumor properties. Moorjani has published two scholarly works, accumulating 28 citations and an h-index of 2. She collaborates with researchers at the University of Arkansas for Medical Sciences, including Robert L. Eoff, Melanie Clair Macnicol, Angus M. MacNicol, and Alicja Urbaniak, with whom she shares co-authored publications.
Metrics
- h-index: 2
- Publications: 2
- Citations: 28
Selected Publications
-
Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models (2021)
-
Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells—in vitro and ex vivo study (2020)
Collaboration Network
Top Collaborators
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
Similar Researchers
Based on overlapping research topics